ANNUAL REPORT THREADBARE (ART) | LUPIN: Rising receivables add to cash flow woes in a weak operating environment
LPC’s FY18 annual report analysis highlights a weak operating performance, with EBITDA declining 31% to INR31.5b, primarily due to continuing pricing pressure in the US market. OCF declined 61% to INR15.5b, as cash conversion days deteriorated to 218 (FY17: 186 days), majorly due to rising trade receivables. Further, inorganic growth continued with the acquisition of Solosec for an upfront cash payout of ~INR3.7b (total consideration: USD124.1m, ~INR8.1b), which led to FCF post interest declining to INR0.6b (FY17: INR13.6b). Our analysis reveals that revenue growth from the acquired subsidiaries has been high; however, their profit contribution has remained muted. Intangibles assets remained elevated at INR46.5b, 34% of NW. This is despite an impairment of INR14.6b recognized on acquired intangibles of the Gavis portfolio. Interestingly, the transfer of IP rights (primarily Gavis) within the group (from Lupin Atlantis Holdings SA to Lupin Inc) before impairment led to a reduction in an otherwise high ETR (at 123%) to 57.2% (FY17: 29.9%).
Op. performance deteriorates, further drag on impairment
High pricing pressure, intensified competition, volatile industry conditions and regulatory challenges in the US markets led to a revenue decline of 10% to INR158b. Further, rising input costs dragged EBITDA by 31% to INR31.5b with margins declining 600bps to 20%. Impairment charges (at INR14.6b) for the Gavis portfolio and higher taxes (ETR at 57.2% v/s 29.9% in FY17) led to a decline in profitability by 90% to INR2.6b.
Lupin is a pharmaceutical company. Co. produces, develops, and markets a range of branded and generic formulations and active pharmaceutical ingredients (APIs) in India, the United States, and Japan. Co. offers various formulations for use in the areas of cephalosporin, cardiovascular (CVS), central nervous system (CNS), anti-asthma, anti-tuberculosis, diabetology, dermatology, gastro intestinal, and other therapy segments; and APIs for use in therapeutic areas of antibiotics, anti-tuberculosis, CVS, CNS, analgesics, and anti-gout. Co. also develops and out-licenses its drug delivery technologies and platforms; and creates and develops biosimilars for various therapeutic indications.
Motilal Oswal Financial Services Ltd. is a reputed name in Financial Services and Online Trading with group companies providing services such as Private Wealth Management, Retail Broking and Distribution, Institutional Broking, Asset Management, Investment Banking, Private Equity, Commodity Broking, Currency Broking, Principal Strategies & Home Finance.
Motilal Oswal Securities is a group company of Motilal Oswal Financial Service Limited which started as a stock trading company and has blossomed into well diversified firm offering a range of financial products and services. Motilal Oswal has built a reputation as the source for best stock trading company and this has taken a wealth of experience, knowledge and expertise, constantly working in tandem, over the years.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.